Katsutoshi Oda - Gynecology

Author Information

Katsutoshi Oda is a distinguished researcher affiliated with the Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Japan. He has made significant contributions to the field of gynecology, particularly in the areas of cervical and endometrial cancer.

Research Contributions

Katsutoshi Oda's research spans various critical aspects of gynecological oncology. In 2022, he published numerous papers addressing diverse topics, such as the treatment of recurrent cervical cancer with nivolumab, the tumor-suppressing role of the LKB1-MARK3 axis in high-grade serous ovarian carcinoma, and the efficacy of pegfilgrastim in endometrial cancer patients. He has also explored the apoptotic effects of CARM1 selective inhibitors in endometrial cancer and investigated genetic diagnoses in pseudomyxoma peritonei originating from ovarian teratomas. His work also extends to precision medicine in gynecological cancer, automated systems for diagnosing endometrial cancer using deep-learning technology, and innovative treatments for cervical intraepithelial neoplasia. These contributions highlight his comprehensive approach to improving cancer diagnosis, treatment, and patient outcomes.

Aliases

Katsutoshi Oda is also known by the names K. Oda and K Oda.

Publication and Citation Metrics

Metric	Value
Citation Count	5721
H-index	39
Paper Count	268

Publications:

Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial.

DOI: 10.1111/jog.15240

Year: 2022

The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma

DOI: 10.1038/s42003-021-02992-4

Year: 2022

Effect of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin.

DOI: 10.1016/j.tjog.2022.02.013

Year: 2022

Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer.

DOI: 10.1016/j.bbrc.2022.02.086

Year: 2022

Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey.

DOI: 10.1038/s10038-022-01028-x

Year: 2022

Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma

DOI: 10.1186/s12920-022-01188-x

Year: 2022

MED1, A Novel Binding partner of BRCA1, Regulates Homologous Recombination and R-Loop Processing

DOI: 10.21203/rs.3.rs-1197248/v1

Year: 2022

Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy

DOI: 10.1371/journal.pone.0248526

Year: 2021

A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing Lactobacillus, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)

DOI: 10.3390/vaccines9040329

Year: 2021

PSY1-5 Precision medicine in gynecological cancer

DOI: 10.1016/J.ANNONC.2021.05.394

Year: 2021

How Do Gametes Meet for Fertilization?

Why is a Liver Biopsy Relevant in Gynecology?

What are Autosomal Recessive Disorders?

Can PCOS be Prevented?

Where Can I Find More Information?

How is a Chancre Identified?

Are There Natural Remedies for Common Gynecological Issues?

What is High Risk Endometrial Cancer?

What Role Does Informed Consent Play?

Can Fentanyl be Used for Chronic Pelvic Pain in Gynecology?

Partnered Content Networks

Relevant Topics